Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ISIS Pharmaceuticals, Inc. : Law Offices of Howard G. Smith Announces Class Action Lawsuit Against ISIS Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/26/2013 | 08:35pm CEST

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all purchasers of the common stock of ISIS Pharmaceuticals, Inc. ("ISIS" or the "Company") (NASDAQ:ISIS) between March 29, 2012 and October 15, 2012, inclusive (the "Class Period").

ISIS engages in the discovery and development of drugs utilizing antisense technology, primarily to treat cardiovascular, metabolic, severe and rare diseases, as well as cancer. The Complaint alleges that throughout the Class Period the Company and certain of its executive officers issued materially false and misleading statements regarding the safety and efficacy of the Company's flagship product, Kynamro (mipomersen sodium), for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Specifically, the Complaint alleges that defendants, through a series of materially false and misleading statements regarding the safety and efficacy of the product, and reportedly positive results from Kynamro's clinical trials, conditioned investors to believe that Kynamro would receive approval from the U.S. Food and Drug Administration (FDA).

On October 16, 2012 the FDA published a clinical briefing document raising concerns regarding the safety and efficacy of Kynamro, noting among other things, abnormal growths or neoplasms developed in 3.1% of patients treated with Kynamro, as compared to only 0.9% of patients who took a placebo; that the data submitted by the Company was limited by a small sample size and a short treatment time, and that during the clinical testing two patients treated with Kynamro died of heart attacks and another patient died of acute liver failure. The FDA report concluded that this "imbalance in neoplasms will need to be assessed further in on-going and future studies and post-marketing (if approved)," and that "the potential for a contributing effect of mipomersen cannot be ruled out" in the patient deaths. As a result of these disclosures, ISIS shares declined nearly 22%, to close at $10.27 on October 16, 2012.

No class has yet been certified in this action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased ISIS common stock during the Class Period, you have certain rights, and have until February 26, 2013 to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
05/25 IONIS PHARMACEUTICALS : Announces Phase 3 NEURO-TTR Study of Inotersen IONIS-TTR..
05/25 IONIS PHARMACEUTICALS : Akcea Announces Publication in The New England Journal o..
05/18 IONIS PHARMACEUTICALS, INC. (NASDAQ : IONS) Files An 8-K Other Events
05/18 IONIS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (for..
05/16 IONIS PHARMACEUTICALS : Announces Phase 3 Results for Inotersen
05/16 IONIS PHARMACEUTICALS INC : Blog Coverage: Ionis Pharma Reported Positive Phase ..
05/16 IONIS PHARMACEUTICALS : shares fall on clinical trial death, but trial succeeds
05/15 IONIS PHARMACEUTICALS : Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TT..
05/11 IONIS PHARMACEUTICALS : Provides Corporate Update at 2017 Annual Meeting of Stoc..
05/10 IONIS PHARMACEUTICALS : to Present at Bank of America Merrill Lynch 2017 Healthc..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Financials ($)
Sales 2017 374 M
EBIT 2017 -14,1 M
Net income 2017 -50,9 M
Finance 2017 186 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 14,9x
EV / Sales 2018 12,2x
Capitalization 5 746 M
More Financials
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 45,2 $
Spread / Average Target -2,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%5 746
INCYTE CORPORATION38.04%28 343
QUINTILES IMS HOLDINGS..10.74%18 637
LONZA GROUP AG23.45%15 409
CELLTRION, INC.--.--%10 281
SEATTLE GENETICS, INC.27.82%9 422
More Results